FAIR ACT

H.R. 7953 would create a new pathway for faster approval of innovative medicines for rare diseases in the United States. The bill would allow the Food and Drug Administration to grant reciprocal marketing approval to drugs and medical products that have already been approved by trusted international regulatory authorities, without requiring the full FDA approval process.

The bill's proponents argue that the lengthy FDA regulatory process delays patient access to life-saving treatments and causes clinical trials to move abroad. By recognizing approvals from trusted international regulators, the bill aims to accelerate access to innovative therapies for Americans with rare diseases while maintaining safety standards. The FDA would retain authority to withdraw or suspend approval if new evidence demonstrates unreasonable risks or if the international regulatory authority rescinds its approval.

The bill would require the FDA to report to Congress within five years on the program's effectiveness, including how many reciprocal approvals were granted or denied. If enacted, this could potentially reduce the time patients wait for access to new rare disease treatments, though the bill is currently under committee review and has not yet been voted on by the full House.